Medical-device reimbursement listing

01Overview and value chain#

Markers EC: Medical-device coding, coverage & reimbursement listing services | OECD: Bioeconomy policy & governance | Regulator: FDA (US)

Medical-device reimbursement listing is a B2B services category in which specialist consultancies secure the CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings a medical device needs to be paid for in clinical use — a step distinct from, and often more commercially decisive than, FDA clearance itself. MCRA runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy. Avalere Health integrates clinical, coding and reimbursement strategy from early development, arguing that early-integrated strategies transform market-access challenges into successful launches with clear coverage and payment pathways. Boston Strategic Partners combines business and clinical strategy with health-economics and outcomes research (HEOR) and medical/technical writing to support device reimbursement dossiers. Emergo by UL, a global QA/RA consulting firm, extends its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance. Real Endpoints is a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices. Vintura, based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device or medicine can offer and what patients actually receive.

The key directions of medical-device reimbursement listing are:

CPT/HCPCS coding strategy: securing or navigating the billing codes (Current Procedural Terminology, Healthcare Common Procedure Coding System) a device needs for a provider to bill for its use.
Payer coverage-policy navigation: working with commercial insurers and public payers to establish a coverage policy under which the device is eligible for payment.
Health-economics and outcomes research (HEOR): building the clinical and economic evidence dossier payers require to justify a coverage or reimbursement decision.
European and national reimbursement-system policy shaping: advising on the specific health-technology-assessment and reimbursement-listing processes of individual national systems outside the US.

Sectoral value chain#

[FDA clearance/approval] ──> [CPT/HCPCS coding strategy] ──> [Payer coverage-policy submission]
                                                                    │
                                                        (HEOR evidence-dossier development)
                                                                    │
              [Ongoing coverage-policy monitoring] <──── [Reimbursement decision & listing] <─── [Payer review & negotiation]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Regulatory clearance	The device receives FDA clearance or approval, the prerequisite before a reimbursement pathway can be pursued.	In: Regulatory submission. Out: Cleared/approved device.
Coding strategy	Determining and securing the CPT/HCPCS billing codes a provider needs to bill for the device’s use.	In: Cleared/approved device, procedure description. Out: Assigned or requested billing code.
Coverage-policy submission	Submitting evidence to commercial and public payers to establish a coverage policy for the device.	In: Billing code, clinical evidence. Out: Coverage-policy submission.
Payer review and negotiation	Payers review the submission, often requesting additional health-economics evidence before deciding.	In: Coverage-policy submission. Out: Payer review outcome.
Reimbursement decision and listing	The payer issues a coverage decision and, where applicable, the device is added to a formal reimbursement listing.	In: Payer review outcome. Out: Coverage decision, reimbursement listing.
Ongoing coverage-policy monitoring	Tracking payer coverage-policy changes and prior-authorization requirements that affect the device’s ongoing reimbursement status.	In: Reimbursement listing. Out: Maintained reimbursement status.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

CPT/HCPCS coding strategy: the specific process of determining and securing the billing codes a medical device needs for a provider to be paid for its use.
Payer coverage-policy analytics: structured tracking and analysis of commercial and public payer coverage policies relevant to a specific device category.
Market-access consulting: integrated advisory services combining regulatory, coding, coverage and HEOR expertise to build a full reimbursement pathway.

02US#

The United States hosts the largest concentration of medical-device reimbursement consultancies, several combining FDA regulatory practices with dedicated coding and payer-coverage expertise.

MCRA’s combined regulatory-reimbursement practice, Avalere’s integrated coding strategy, Boston Strategic Partners’ HEOR support, Emergo by UL’s global QA/RA-adjacent work, Real Endpoints’ payer-coverage focus#

MCRA: runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy.
Avalere Health: integrates clinical, coding and reimbursement strategy from early development, transforming market-access challenges into launches with clear coverage and payment pathways.
Boston Strategic Partners: combines business and clinical strategy with health-economics and outcomes research and medical/technical writing to support device reimbursement dossiers.
Emergo by UL: a global QA/RA consulting firm extending its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance.
Real Endpoints: a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices.

03CN#

China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese medical-device reimbursement consultancies searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Medical-device reimbursement listing in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog processes rather than the payer-by-payer model common in the US and Europe, and specialist consulting practices supporting this process could not be confirmed in this screen.

China’s centralized medical-insurance listing process without a confirmed specialist consultancy#

Centralized listing model: device reimbursement in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog listing process, structurally distinct from the multi-payer US model.
Domestic gap: no Chinese-headquartered medical-device reimbursement consultancy confirmed by a live 2026 source was found during this screen.

04EU#

Europe hosts market-access and policy-shaping consultancies working across the fragmented national health-technology-assessment and reimbursement-listing systems of individual EU member states.

Vintura’s policy-shaping and commercial-strategy practice across European reimbursement systems#

Vintura: based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device can offer and what patients actually receive under national coverage decisions.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
MCRA	🇺🇸 USA	Regulatory + reimbursement consulting	Combined FDA 510(k) and CPT/HCPCS practice	commercial
Avalere Health	🇺🇸 USA	Integrated market-access advisory	Clinical/coding/reimbursement strategy	commercial
Boston Strategic Partners	🇺🇸 USA	Business & clinical strategy	HEOR and medical/technical writing	commercial
Emergo by UL	🇺🇸 USA	Global QA/RA consulting	FDA 510(k)/De Novo/PMA-adjacent reimbursement work	commercial
Real Endpoints	🇺🇸 USA	Payer-coverage advisory	Commercial/private-payer coverage focus	commercial
Vintura	🇳🇱 Netherlands	European market-access consulting	Policy shaping across EU reimbursement systems	commercial

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The medical-device reimbursement listing stack combines regulatory-adjacent coding expertise with structured payer-coverage analytics and health-economics evidence development:

CPT/HCPCS coding strategy:
- Firms such as MCRA and Avalere Health determine and secure the specific billing codes a device needs, a step that directly determines whether providers can be paid for using it.
Payer coverage-policy analytics:
- Real Endpoints specializes in tracking and navigating commercial and private-payer coverage policy and prior-authorization requirements specific to a device category.
HEOR evidence development:
- Boston Strategic Partners builds the health-economics and outcomes research evidence dossier payers require to justify a coverage or reimbursement decision.

07Value chains and production pipelines#

Industrial pipeline for a medical-device reimbursement listing engagement#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Regulatory clearance     │ ───> │ 2. CPT/HCPCS coding         │
│                                  │      │    strategy                       │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Payer review &           │ <─── │ 3. Coverage-policy          │
│    negotiation                  │      │    submission                     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Reimbursement decision   │ ───> │ 6. Ongoing coverage-        │
│    & listing                    │      │    policy monitoring              │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline for a medical-device reimbursement listing engagement

Stage 1: Regulatory clearance

The device receives FDA clearance or approval, the prerequisite step before a reimbursement pathway can be pursued.

Stage 2: CPT/HCPCS coding strategy

The consultancy determines and secures the billing codes a provider needs to bill for the device’s use, requesting a new code where none exists.

Stage 3: Coverage-policy submission

Evidence supporting the device’s clinical and economic value is submitted to commercial and public payers to establish a formal coverage policy.

Stage 4: Payer review and negotiation

Payers review the submission, often requesting additional health-economics evidence or negotiating specific coverage terms before deciding.

Stage 5: Reimbursement decision and listing

The payer issues a coverage decision, and where applicable, the device is added to a formal reimbursement listing that providers can bill against.

Stage 6: Ongoing coverage-policy monitoring

The consultancy tracks payer coverage-policy changes and prior-authorization requirements that could affect the device’s ongoing reimbursement status.

Supplier	Region & tags
MCRA	US
Avalere Health	US
Boston Strategic Partners	US
Emergo by UL	US
Real Endpoints	US
Vintura	EU

AI Recommendation

Key directions:

CPT/HCPCS coding strategy — securing or navigating the billing codes a device needs for a provider to bill for its use.
Payer coverage-policy navigation — working with commercial insurers and public payers to establish a coverage policy under which the device is eligible for payment.
Health-economics and outcomes research (HEOR) — building the clinical and economic evidence dossier payers require to justify a coverage decision.
European and national reimbursement-system policy shaping — advising on the specific health-technology-assessment and listing processes of individual national systems outside the US.

Regulatory:

FDA clearance or approval is the prerequisite step, but it does not itself guarantee reimbursement — a cleared device with no assigned billing code or payer coverage policy may still be commercially unusable.
Payer coverage decisions are made independently by each commercial insurer and public payer program, which is why a device can be cleared nationally but only partially reimbursed depending on the specific payer.
Outside the US, national health-technology-assessment bodies run their own listing processes, structurally distinct from the US payer-by-payer model.

Companies not in table: Health Advances, a US market-access strategy consultancy, was confirmed by a live source but held back to keep the table at six rows and open a slot for the one confirmed European candidate (Vintura); Xcenda and a Chinese candidate returned no confirming live source and were excluded rather than tabled from general knowledge.

Category boundary: this is distinct from general FDA regulatory-clearance consulting — clearance answers whether a device may be sold; reimbursement listing answers whether anyone will actually be paid to use it, and a firm can clear the first hurdle and still fail the second.

Processing note: only US and EU candidates confirmed on this screen; China’s centralized medical-insurance catalog process is described qualitatively rather than through an unconfirmed vendor.